Insulet to Webcast Investor Day on November 16, 2016
November 04 2016 - 08:00AM
Business Wire
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the
leader in tubeless insulin pump technology with its Omnipod®
Insulin Management System, today announced it will host an Investor
Day on November 16, 2016, in Boston, Massachusetts. The
presentation will begin at 10:30 a.m. (Eastern Time) followed by a
question and answer session, and is expected to end at 2:00 p.m.,
with product exhibits to follow. The day will end at 3:00 p.m. The
presentation will be webcast live and may be accessed via Insulet’s
website at http://investors.insulet.com under the Investor
Relations section. Materials accompanying the presentation will
also be posted within this section under "Events and Presentations"
following the event.
Presentations will be given by the following members of
management:
- Patrick Sullivan, Chairman and Chief
Executive Officer
- Shacey Petrovic, President and Chief
Operating Officer
- Aiman Abdel-Malek, Senior Vice
President, Advanced Technology and Engineering
- Charles Alpuche, Senior Vice President,
Global Manufacturing and Operations
- Michael Levitz, Senior Vice President
and Chief Financial Officer
In addition, the Company will hold a panel discussing the
Company’s Artificial Pancreas program, featuring members of the
management team, including Dr. Trang Ly, Vice President and Medical
Director.
For those unable to join the live webcast, a replay will be
available following the event and can be accessed at
http://investors.insulet.com.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical
device company dedicated to making the lives of people with
diabetes easier. Through its Omnipod Insulin Management System,
Insulet seeks to expand the use of insulin pump therapy among
people with insulin-dependent diabetes. The Omnipod is a
revolutionary and easy-to-use tubeless insulin pump that features
just two parts and a fully-automated cannula
insertion. Insulet's Delivery Systems business also partners
with global pharmaceutical and biotechnology companies to tailor
the Omnipod technology platform for the delivery of subcutaneous
drugs across multiple therapeutic areas. Founded in 2000, Insulet
Corporation is based in Billerica, Massachusetts. For more
information, please visit: http://www.myomnipod.com.
Forward-Looking Statements:
This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations,
intentions, beliefs or strategies regarding the future. These
forward-looking statements are based on its current expectations
and beliefs concerning future developments and their potential
effects on Insulet. There can be no assurance that future
developments affecting Insulet will be those that it has
anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or
other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties
described in its Annual Report on Form 10-K, which was filed with
the Securities and Exchange Commission on February
29, 2016 in the section entitled "Risk Factors," and in its
other filings from time to time with the Securities and
Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should any of its assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking
statements. Insulet undertakes no obligation to publicly
update or revise any forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161104005035/en/
Investor Relations and Media Contact:Insulet
CorporationDeborah R. Gordon, 978-600-7717Vice President, Investor
Relations and Corporate Communicationsdgordon@insulet.com
Insulet (NASDAQ:PODD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Insulet (NASDAQ:PODD)
Historical Stock Chart
From Mar 2023 to Mar 2024